首页 > 市场调查报告书 > 医疗设备

体外诊断生技设备

市场调查报告书

商品编码

1738547

2026 年至 2032 年免疫组织化学 (IHC) 市场（按产品、应用、最终用户和地区划分）

Immunohistochemistry (IHC) Market By Product (Antibodies, Reagents), Application (Diagnostic, Research), End-User (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), & Region for 2026-2032

出版日期: 2025年05月12日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

免疫组织化学（IHC）市场评估 - 2026-2032

全球癌症患者数量的不断增长推动了免疫组织化学 (IHC) 的应用。 IHC 技术的创新提高了其敏感度和特异性，吸引了更多研究人员和临床医生的注意。预计 2024 年 IHC 市场规模将超过 20.6 亿美元，到 2032 年将达到约 33.7 亿美元。

此外，政府对癌症研究的有利法规和资金支持也推动了免疫组织化学 (IHC) 的应用。个人化治疗的转变推动了对 IHC 精准生物标记的需求，预计这将推动市场在 2026 年至 2032 年期间以 6.37% 的复合年增长率成长。

免疫组织化学（IHC）市场：定义/概述

免疫组织化学 (IHC) 是一种实验室技术，利用基于抗体的染色来观察组织切片中特定蛋白质的存在和位置。此方法利用抗体与标靶抗原结合的特异性，使研究人员和临床医生能够识别细胞结构并了解组织的病理变化。通常，组织会经过固定、切片，并用与可检测标记物偶联的抗体处理，以便在显微镜下进行观察。

免疫组化 (IHC) 广泛应用于临床诊断和研究。在病理学中，它透过识别肿瘤标记和细胞分化，在诊断包括癌症在内的各种疾病中发挥着至关重要的作用。此外，IHC 也用于基础研究，以研究蛋白质表现模式、细胞定位以及治疗对特定细胞路径的影响。它能够为蛋白质表现提供空间背景，这对于理解疾病机制和组织结构至关重要。

VMR 内部

产业报告内容

我们的报告包含可操作的数据和前瞻性的分析，可协助您制定宣传方案、建立商业计划、组织简报或撰写提案。

个人化医疗领域不断增长的研发活动将如何促进免疫组织化学 (IHC) 的采用？

全球癌症盛行率的上升是免疫组织化学 (IHC) 市场的主要驱动力。根据世界卫生组织 (WHO) 的数据，2020 年癌症将导致约 1000 万人死亡，乳癌、肺癌、结肠癌和前列腺癌。 IHC 在癌症诊断、预后和治疗计划中发挥关键作用，因此对此类技术的需求不断增长。多重 IHC 和数位病理学等 IHC 技术的最新进展进一步增强了 IHC 在肿瘤学中的效用。 2024 年 3 月，罗氏宣布推出一款全新的自动化 IHC 平台，旨在提高癌症诊断的工作流程效率和准确性。

个人化医疗领域活性化的研发投入正在推动免疫组化（IHC）市场的发展。美国国立卫生研究院 (NIH) 报告称，将在 2023 财政年度拨款 4.19 亿美元用于精准医疗研究。 IHC 技术对于识别特定的生物标记和分子标靶至关重要，从而能够为个别患者制定个人化的治疗策略。这一趋势在针对各种疾病（包括自体免疫和神经退化性疾病）的标靶治疗开发中尤为明显。

新兴经济体对免疫组化（IHC）的日益普及正在推动市场成长。印度医学研究理事会 (ICMR) 报告称，2019 年至 2023 年期间，公立医院的免疫组化检测量将以每年 15% 的速度增长。推动这一趋势的因素包括医疗基础设施的改善、对先进诊断技术的认识不断提高以及这些地区医疗支出的增加。免疫组化在诊断许多新兴国家流行的感染疾病的多功能性，进一步推动了其应用。

不同平台和机构之间的标准化问题是否会阻碍市场成长？

不同平台和实验室之间的标准化问题进一步加剧了IHC领域的复杂性。样本製备、染色方案和解读标准的差异可能导致结果不一致。标准化的缺乏会降低IHC观察的可靠性，尤其是在需要一致性数据的多中心研究和临床实验室。

此外，分子技术和新一代定序等替代技术的出现，正在为IHC市场带来竞争压力。随着这些替代技术变得更加先进和普及，它们可能为蛋白质分析和疾病表征提供更可靠或更具成本效益的解决方案。随着研究人员和临床医生不断寻求新的诊断和研究方法，这种趋势可能会限制IHC的发展和应用。

此外，监管环境对 IHC 市场也构成了挑战：新抗体和诊断试剂套件的核准流程漫长而复杂，这可能会延迟创新产品的推出，严格的监管也会限制某些试剂的可用性，影响市场动态并为希望进入该领域的小公司设置障碍。

F. Agilent Technologies
Roche Diagnostics
Thermo Fisher Scientific
Merck KGaA
Abcam plc
Bio-Rad Laboratories
PerkinElmer, Inc.
Dako（part of Agilent）
Leica Biosystems
Cell Signaling Technology
F. Sigma-Aldrich（Merck）
Miltenyi BIoTec
Genetex, Inc.
Ventana Medical Systems（Roche）
Fujifilm
Biocare Medical
Santa Cruz BIoTechnology
Zymed Laboratories（Thermo Fisher）
NeoGenomics Laboratories
Enzo Life Sciences

第十一章公司简介附录

相关调查

简介目录

Product Code: 60441

Immunohistochemistry (IHC) Market Valuation - 2026-2032

Increasing cancer cases globally is propelling the adoption of immunohistochemistry (IHC). Innovations in IHC techniques enhance sensitivity and specificity, attracting more researchers and clinicians is driving the market size surpass USD 2.06 Billion valued in 2024 to reach a valuation of around USD 3.37 Billion by 2032.

In addition to this, favorable government regulations and funding for cancer research is spurring up the adoption of immunohistochemistry (IHC). The shift towards tailored therapies boosts the need for precise biomarkers identified through IHC, this is enabling the market grow at a CAGR of 6.37% from 2026 to 2032.

Immunohistochemistry (IHC) Market: Definition/ Overview

Immunohistochemistry (IHC) is a laboratory technique used to visualize the presence and location of specific proteins in tissue sections using antibody-based staining. This method leverages the specificity of antibodies to bind to target antigens, allowing researchers and clinicians to identify cellular structures and understand pathological changes in tissues. Typically, tissues are fixed, sectioned, and treated with antibodies that are linked to a detectable marker, enabling visualization under a microscope.

IHC is widely utilized in both clinical diagnostics and research. In pathology, it plays a crucial role in diagnosing various diseases, including cancers, by identifying tumor markers and cellular differentiation. Additionally, IHC is used in basic research to study protein expression patterns, cellular localization, and the effects of treatments on specific cellular pathways. Its ability to provide spatial context to protein expression makes it invaluable in understanding disease mechanisms and tissue architecture.

What's inside a VMR

industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How will Rising Research and Development Activities in the Field of Personalized Medicine Increasing Adoption of Immunohistochemistry (IHC)?

The growing prevalence of cancer worldwide is a significant driver of the Immunohistochemistry (IHC) market. According to the World Health Organization, cancer was responsible for nearly 10 million deaths in 2020, with breast, lung, colon, and prostate cancers being the most common types. IHC plays a crucial role in cancer diagnosis, prognosis, and treatment planning, leading to increased demand for these techniques. Recent advancements in IHC technologies, such as multiplex IHC and digital pathology, have further enhanced its utility in oncology. In March 2024, Roche announced the launch of its new automated IHC platform, aiming to improve workflow efficiency and accuracy in cancer diagnostics.

Increasing research and development activities in the field of personalized medicine are propelling the IHC market forward. The U.S. National Institutes of Health (NIH) reported allocating $419 million for precision medicine research in the fiscal year 2023. IHC techniques are essential for identifying specific biomarkers and molecular targets, enabling tailored treatment strategies for individual patients. This trend is particularly evident in the development of targeted therapies for various diseases, including autoimmune disorders and neurodegenerative conditions.

The rising adoption of IHC in emerging economies is driving market growth. The Indian Council of Medical Research (ICMR) reported a 15% annual increase in IHC test volumes across public hospitals from 2019 to 2023. Factors contributing to this trend include improving healthcare infrastructure, increasing awareness about advanced diagnostic techniques, and growing healthcare expenditure in these regions. IHC's versatility in diagnosing infectious diseases, which are prevalent in many developing countries, further fuels its adoption.

Will Issues of Standardization across Different Platforms and Institutions Hindering the Market Growth?

The issue of standardization across different platforms and institutions further complicates the IHC landscape. Variability in sample preparation, staining protocols, and interpretation criteria can lead to discrepancies in results. This lack of standardization can undermine confidence in IHC findings, particularly in multicenter studies or clinical trials where consistent data is essential.

Also, the emergence of alternative technologies, such as molecular techniques and next-generation sequencing, presents competitive pressure on the IHC market. As these alternatives become more advanced and accessible, they may offer more reliable or cost-effective solutions for protein analysis and disease characterization. This trend could potentially limit the growth and application of IHC, as researchers and clinicians explore new methods for their diagnostic and research needs.

Additionally, the regulatory landscape poses challenges for the IHC market. The approval processes for new antibodies and diagnostic kits can be lengthy and complex, slowing down the introduction of innovative products. Stringent regulations can also limit the availability of certain reagents, affecting the market dynamics and creating barriers for smaller companies aiming to enter the field.

Category-Wise Acumens

Which Factors are Contributing Antibodies Segment Dominance in Immunohistochemistry (IHC) Market?

Antibodies are at the forefront of the Immunohistochemistry (IHC) market, playing a crucial role in detecting and visualizing specific antigens in tissue samples. Primary antibodies, in particular, are essential for precise target identification and are available in both monoclonal and polyclonal forms. According to the National Cancer Institute, over 80% of cancer diagnoses in the United States involved IHC techniques in 2023, highlighting the widespread use of antibodies in clinical settings. The continuous development of highly specific and sensitive antibodies has significantly improved the accuracy and reliability of IHC assays.

The demand for multiplex IHC antibodies is rapidly growing, driven by the need to analyze multiple biomarkers simultaneously in complex diseases like cancer. The U.S. Food and Drug Administration (FDA) approved 14 companion diagnostic IHC tests between 2020 and 2023, many of which utilize multiplex antibody panels. This trend reflects the increasing importance of comprehensive molecular profiling in personalized medicine. Multiplex IHC allows researchers and clinicians to gain deeper insights into cellular interactions and disease mechanisms, leading to more informed treatment decisions.

Which Factors Enhance the Use of Immunohistochemistry (IHC) for Diagnostics?

Diagnostics continue to dominate the Immunohistochemistry (IHC) market, with cancer diagnosis being a primary application. IHC techniques are crucial for identifying specific biomarkers, determining tumor origin, and guiding treatment decisions in oncology. According to the National Cancer Institute, approximately 1.9 million new cancer cases were diagnosed in the United States in 2023, emphasizing the ongoing need for accurate diagnostic tools. The ability of IHC to provide detailed information about protein expression and cellular localization makes it indispensable in modern pathology laboratories.

IHC diagnostics are increasingly being utilized in the field of infectious diseases, particularly for identifying pathogens that are difficult to culture or detect through other methods. The Centers for Disease Control and Prevention (CDC) reported that IHC was used in 15% of challenging infectious disease cases in 2023, up from 10% in 2020. This trend has been accelerated by recent global health events, highlighting the need for rapid and accurate diagnostic techniques. IHC's ability to detect viral antigens in tissue samples has proven especially valuable in diagnosing and studying emerging infectious diseases.

Country/Region-wise Acumens

Will Presence of Major IHC Market Players in North America Driving Immunohistochemistry (IHC) Market Growth?

North America maintains its dominant position in the immunohistochemistry (IHC) market, driven by advanced healthcare infrastructure and high adoption rates of cutting-edge diagnostic technologies. The region's leadership is bolstered by substantial investment in research and development, particularly in the fields of oncology and personalized medicine. According to the National Cancer Institute, cancer research funding in the United States reached $7.1 billion in fiscal year 2023, highlighting the country's commitment to advancing diagnostic and treatment capabilities. This investment directly translates to increased demand for sophisticated IHC techniques and products. In January 2024, Roche Diagnostics unveiled its next-generation IHC platform in the U.S. market, featuring enhanced automation and improved staining consistency for more accurate diagnoses.

The presence of major IHC market players and a robust regulatory framework contribute significantly to North America's market dominance. The U.S. Food and Drug Administration (FDA) approved 28 IHC-based companion diagnostic tests between 2020 and 2023, underscoring the region's leadership in translating research into clinical applications. These approvals facilitate the integration of IHC diagnostics into standard clinical practice, particularly in oncology. The region's large and aging population, coupled with high healthcare expenditure, further drives market growth. In March 2024, Leica Biosystems, a key player in the North American market, announced a strategic partnership with a leading artificial intelligence company to develop AI-powered IHC image analysis tools, aimed at improving diagnostic accuracy and efficiency.

Will Rising Prevalence Of Cancer Enhance Adoption of Immunohistochemistry (IHC) in Asia Pacific?

The Asia Pacific region is experiencing rapid growth in the Immunohistochemistry (IHC) market, driven by increasing healthcare expenditure, rising cancer incidence, and growing awareness of advanced diagnostic techniques. Countries like China, Japan, and India are at the forefront of this expansion, with significant investments in healthcare infrastructure and research capabilities. According to the National Health Commission of China, the country's healthcare spending reached 7.12 trillion yuan (approximately USD 1.1 Trillion) in 2023, representing a substantial increase from previous years. This investment is translating into improved access to advanced diagnostic tools, including IHC. In April 2024, Roche Diagnostics announced the opening of a new IHC reagent manufacturing facility in Shanghai, aiming to meet the growing regional demand and reduce delivery times for critical diagnostic products.

The rising prevalence of cancer in the Asia Pacific region is a key factor driving the adoption of IHC techniques. The Indian Council of Medical Research (ICMR) reported that new cancer cases in India are projected to increase by 12% by 2025, emphasizing the urgent need for accurate and efficient diagnostic methods. This trend is prompting healthcare providers across the region to invest in advanced IHC platforms and expand their diagnostic capabilities. The increasing focus on personalized medicine and targeted therapies is further fueling the demand for IHC-based biomarker testing. In March 2024, Danaher Corporation's Leica Biosystems division launched a new line of IHC antibodies specifically designed for prevalent cancer types in the Asia Pacific region, demonstrating the market's potential for tailored diagnostic solutions.

Competitive Landscape

The immunohistochemistry (IHC) market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the immunohistochemistry (IHC) market include:

Agilent Technologies
Roche Diagnostics
Thermo Fisher Scientific
Merck KGaA
Abcam plc
Bio-Rad Laboratories
PerkinElmer, Inc.
Dako (part of Agilent)
Leica Biosystems
Cell Signaling Technology
Sigma-Aldrich (Merck)
Miltenyi Biotec
Genetex, Inc.
Ventana Medical Systems (Roche)
Fujifilm
Biocare Medical
Santa Cruz Biotechnology
Zymed Laboratories (Thermo Fisher)
NeoGenomics Laboratories
Enzo Life Sciences

Latest Developments

In September 2023, Thermo Fisher Scientific launched a new line of advanced antibodies specifically designed for immunohistochemistry applications, enhancing sensitivity and specificity in cancer diagnostics.
In August 2023, Bio-Techne announced a collaboration with leading academic institutions to develop novel multiplex IHC techniques, enabling simultaneous detection of multiple biomarkers in tissue samples.

1 INTRODUCTION OF GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET, BY PRODUCT

5.1 Overview
5.2 Antibodies
5.3 Reagents
5.4 Equipment
5.5 Kits

6 GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET, BY APPLICATION

6.1 Overview
6.2 Diagnostic
6.3 Research
6.4 Forensic

7 GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET, BY END USER

7.1 Overview
7.2 Hospitals & Diagnostic Laboratories
7.3 Academic & Research Institutes
7.4 Others

8 GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 F. Agilent Technologies
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Roche Diagnostics
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Thermo Fisher Scientific
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Merck KGaA
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Abcam plc
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Bio-Rad Laboratories
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 PerkinElmer, Inc.
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Dako (part of Agilent)
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Leica Biosystems
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Cell Signaling Technology
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments
10.11 F. Sigma-Aldrich (Merck)
- 10.11.1 Overview
- 10.11.2 Financial Performance
- 10.11.3 Product Outlook
- 10.11.4 Key Developments
10.12 Miltenyi Biotec
- 10.12.1 Overview
- 10.12.2 Financial Performance
- 10.12.3 Product Outlook
- 10.12.4 Key Developments
10.13 Genetex, Inc.
- 10.13.1 Overview
- 10.13.2 Financial Performance
- 10.13.3 Product Outlook
- 10.13.4 Key Developments
10.14 Ventana Medical Systems (Roche)
- 10.14.1 Overview
- 10.14.2 Financial Performance
- 10.14.3 Product Outlook
- 10.14.4 Key Developments
10.15 Fujifilm
- 10.15.1 Overview
- 10.15.2 Financial Performance
- 10.15.3 Product Outlook
- 10.15.4 Key Developments
10.16 Biocare Medical
- 10.16.1 Overview
- 10.16.2 Financial Performance
- 10.16.3 Product Outlook
- 10.16.4 Key Developments
10.17 Santa Cruz Biotechnology
- 10.17.1 Overview
- 10.17.2 Financial Performance
- 10.17.3 Product Outlook
- 10.17.4 Key Developments
10.18 Zymed Laboratories (Thermo Fisher)
- 10.18.1 Overview
- 10.18.2 Financial Performance
- 10.18.3 Product Outlook
- 10.18.4 Key Developments
10.19 NeoGenomics Laboratories
- 10.19.1 Overview
- 10.19.2 Financial Performance
- 10.19.3 Product Outlook
- 10.19.4 Key Developments
10.20 Enzo Life Sciences
- 10.20.1 Overview
- 10.20.2 Financial Performance
- 10.20.3 Product Outlook
- 10.20.4 Key Developments